Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1321587
This article is part of the Research Topic Advances in the use of EGFR TKIs in the Treatment of NSCLC View all 18 articles

EGFR kinase domain duplication (EGFR-KDD) in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: A case report and literature review

Provisionally accepted
Hong Lin Hong Lin Zhifeng Li Zhifeng Li *Zhengyuan Yang Zhengyuan Yang *Junwei Chen Junwei Chen *Hongbiao Wang Hongbiao Wang *
  • Cancer Hospital, College of Medicine, Shantou University, Shantou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Background: EGFR kinase domain duplication (EGFR-KDD) is an infrequent oncogenic driver mutation in lung adenocarcinoma. It may be a potential target benefit from EGFR-tyrosine kinase inhibitors (TKIs) treatment.Case presentation: A 66-year-old Chinese male was diagnosed with lung adenocarcinoma in stage IVb with brain metastases. Next-generation sequencing revealed EGFR-KDD mutation. The patient received furmonertinib 160mg daily for anti-cancer treatment and obtained therapeutic efficacy with partial response (PR). Progression-free survival (PFS) duration from monotherapy was 16 months. With slow progressions, combined radiotherapy and antivascular targeted therapy also brought a continuous decrease in the tumors. The patient has an overall survival (OS) duration of more than 22 months and still benefits from double-dose furmonertinib.Conclusions: This report provided direct evidence for the treatment of EGFR-KDD to use furmonertinib. A Large-scale study is needed to confirm this preliminary finding.

    Keywords: EGFR-KDD, furmonertinib, brain metastasis, Lung Adenocarcinoma, targeted therapy

    Received: 14 Oct 2023; Accepted: 06 May 2024.

    Copyright: © 2024 Lin, Li, Yang, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhifeng Li, Cancer Hospital, College of Medicine, Shantou University, Shantou, Guangdong Province, China
    Zhengyuan Yang, Cancer Hospital, College of Medicine, Shantou University, Shantou, Guangdong Province, China
    Junwei Chen, Cancer Hospital, College of Medicine, Shantou University, Shantou, Guangdong Province, China
    Hongbiao Wang, Cancer Hospital, College of Medicine, Shantou University, Shantou, Guangdong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.